NetworkNewsWire
Editorial Coverage: Drugs play an essential role in treating
anything from a mild headache to life-threatening disease — and
everything in between. While effectiveness of drugs is what most
often captures the spotlight, that effectiveness is closely
associated with the drug-delivery technology used, and innovation
in this space may have a huge impact on how successful a drug can
be.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
(LXRP
Profile) has developed one of the most innovative
drug-delivery systems seen in years, a system that can be used to
deliver a wide range of drugs in a more palatable and effective
way. Seattle Genetics Inc. (NASDAQ: SGEN) is
developing anti-cancer drugs whose delivery systems deliver killer
treatments directly to harmful cells. Cancer-treatment company
Exelixis Inc. (NASDAQ: EXEL) has recently entered
into a partnership specifically to develop innovative new drugs.
Axsome Therapeutics Inc. (NASDAQ: AXSM) uses a
variety of delivery mechanisms to treat illnesses of the central
nervous system, including narcolepsy, migraines and depression.
Provention Bio Inc. (NASDAQ: PRVB) is focused on
immune diseases and has recently seen significant progress in the
development of lupus and diabetes drugs.
- New methods of delivery could make many drugs more
effective.
- The delivery systems can be applied to everything from nicotine
to cancer treatments.
- Investment and outside expertise have helped fuel the companies
developing these treatments.
To view an infographic of this editorial, click here.
Seeking Innovations in Therapeutics
The search for innovation is vital in any sector but
particularly so in health and medicine. While existing products can
sometimes be rebranded or improved, the genuinely transformative
are focused on saving lives and improving the well-being of
patients around the world.
Innovations in bioscience aren’t always dramatic. Some, such as
gene therapy or new treatments for viruses, can easily grab the
headlines. But other improvements can also make a radical
difference to people’s lives, from making treatments more
affordable to making medicines more palatable and efficient,
allowing patients to complete courses of treatment. Innovative new
delivery systems can achieve these goals and are therefore among
the most highly sought-after advances by companies in the fields of
medicine, biotechnology and even consumer products.
New Approaches to Nicotine
One important area where this type of innovation has been
particularly effective is the delivery of nicotine, in which
Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is making
momentous advances.
Despite public health campaigns and legislative changes, tobacco
remains a major health problem around the world. Lung cancer is one
of the deadliest cancers and, in 85% of cases, is linked to
smoking. Even smokers who get lucky and dodge the cancer bullet pay
the heavy costs of addiction, from its expense to distinctive odors
and respiratory problems.
Because of nicotine’s addictive quality, many people find it
difficult to break the hold tobacco has over their lives, their
health and their wallets. Until recently, innovation in the
nicotine industry was almost zero, with the creation of nicotine
patches and gums having occurred decades ago.
Vaping, by virtue of retaining some of smoking’s ritual and
social aspects, has become a popular alternative, but there is
great uncertainty over how healthy it is, and only longitudinal
studies will allow public-health organizations to find the answer.
Lexaria’s nicotine-delivery technology may represent the single
largest innovation in the nicotine industry in 30 years.
Lexaria’s DehydraTECH(TM) technology can be used to deliver
nicotine in a safer way. By ingeniously combining nicotine with
food-grade fatty acids, the patented DehydraTECH technology creates
an oral form of nicotine delivery that does not target the lungs
and does not cause lung cancer. Neither is the nicotine absorbed as
an aerosol — the plague of the ongoing and growing vape
epidemic.
And this appears to be only the beginning of where this
innovative drug-delivery platform may change the landscape.
A Novel Approach to Drug Absorption
DehydraTECH may be the most novel form of drug
delivery discovered in decades. Fatty acids used in the
technology mask the smell and taste of the drug and potentially
greatly reduce stomach upset. This allows it to be added to all
sorts of foods and drinks — oral delivery — without relying on
artificial flavors or loads of sugar to mask a drug. This is useful
not just for nicotine but for other pharmaceuticals as well.
In addition to covering the smells and tastes associated with
drugs, DehydraTECH also improves the delivery of the substances it
contains. One of the reasons smoking is so appealing is because
there are lower barriers for a drug to enter the bloodstream
through the lungs than through the digestive system. Smoking
delivers drugs quickly and effectively but in an unhealthy manner.
DehydraTECH is also designed to deliver drugs quickly and
effectively but in a much healthier method than smoking or
vaping.
DehydraTECH is already patented for delivery of a range of
substances including nicotine, NSAIDs and many more. As markets for
these health and wellness products expand, so will the market for
effective delivery systems. As a result, there’s more need than
ever for a solution such as DehydraTECH.
Establishing Profitable Relationships
Though a relatively young company, Lexaria has already
established positive relationships with companies and investors
from the Fortune 500. Lexaria’s technology is being examined and
may be put into production by one of America’s largest companies
through a R&D and product development agreement and a
technology license whereby Lexaria can receive ongoing royalties
based on utilization of DehydraTECH.
To boost its expansion efforts, Lexaria has appointed Brian Quigley to its board of directors.
Quigley is a former executive at Altria, one of the world’s biggest
tobacco companies, where he spent seven years as president and CEO
for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation
company. His experience, knowledge and connections are valuable
assets that could make a big difference in Lexaria’s push to
demonstrate the value of DehydraTECH both to investors and to
customers.
With tobacco consumers as one of Lexaria’s largest target
markets for noncombusted nicotine delivery, an ex-tobacco executive
is a natural fit. But there’s more to Lexaria’s expansion than
investment hunting and careful boardroom choices.
Groundbreaking Research
Lexaria’s growth, like that of any good biotech company, is
founded in its R&D program. Through groundbreaking work with the National Research Council of
Canada (NRC), Lexaria has improved understanding of what is
happening in its technology, down to the molecular level. Rigorous
testing, including liquid chromatography high-resolution mass
spectrometry and nuclear magnetic resonance, demonstrated that the
DehydraTECH process does not create a covalent-bonded new molecular
entity (“NME”), and so will not need the extra regulatory screening
required for NME’s in Canada and the United States.
Meanwhile, the company has continued to innovate in creating its
proprietary technology and to ensure it retains control of its
creations. In August, Lexaria received five new granted patents: two in the United States and
three in Australia. This brings the company’s total up to 16
patents, all revolving around its DehydraTECH process and the
products stemming from it.
Lexaria’s newest patent awards also include — for the first time
—granted claims for pharmaceutical applications for treatment of
conditions such as heart disease, Alzheimer’s, Parkinson’s, hepatic
disease, and alcohol, opioid, nicotine or cocaine addiction, among
others. Lexaria appears to have established itself as an
noteworthy, up-and-coming player within the biotech industry.
And Lexaria isn’t keeping its revolutionary technology to
itself. Instead, the company is licensing DehydraTECH out to other
companies, allowing those companies to use the technology to
improve delivery of their own drugs and compounds. Eleven licenses have been granted so far, including
one to Altria, which will use DehydraTECH in alternative nicotine
products, and one to Hill Street Beverages for use in beverages
around the world.
Working on Delivery Systems
Delivery systems are a vital component in the drug industry and
are highly sought after. They allow treatments to bypass bodily
defenses that may treat them as intruders and to more effectively
target the site of ailments. That’s why they’re vital to cancer
treatments such as those being developed by Seattle
Genetics Inc. (NASDAQ: SGEN). The company has been
working on antibody-drug conjugate technology,
which can deliver cell-killing agents directly to cancer cells. A
treatment using this technology was recently approved by the FDA.
Exelixis Inc. (NASDAQ: EXEL) has spent 25 years
working on effective cancer treatments. Its industry-leading small
molecule chemical compound library, which consists of more than
four million discrete drug leads, has been used in the development
of three distinct drugs for the treatment of cancer. The company
recently entered into an agreement with
Aurigene Discovery Technologies Limited to work on cancer
medicines with unique action mechanisms.
Axsome Therapeutics Inc. (NASDAQ: AXSM) uses a
variety of delivery mechanisms to treat illnesses of the central
nervous system including narcolepsy, migraines and Alzheimer’s
disease. The company is also working on products to help users quit
smoking. Axsome recently began Phase 3
trials of the use of one of its medicines to tackle major
depressive disorders and has accelerated trials
of a migraine treatment.
For Provention Bio Inc. (NASDAQ: PRVB), the
focus is on immune diseases — both preventing and treating them.
Provention Bio’s central innovation is to focus on earlier stages
of diseases and to tackle them before heavy symptoms set in. The
company recently announced clinical trials of a
drug targeting lupus and has seen its work on a diabetes drug
expedited by the FDA so that treatment will reach
patients faster.
Novel delivery systems are creating new drugs to tackle
everything from tobacco addiction to cancer relief, and such
breakthroughs could be the making of the companies behind them.
For more information on Lexaria, please visit Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to
reach all target markets, industries and demographics in the most
effective manner possible, (2) article and editorial syndication to
5,000+ news outlets (3), enhanced press release services to ensure
maximum impact, (4) social media distribution via the Investor
Brand Network (IBN) to nearly 2 million followers, (5) a full array
of corporate communications solutions, and (6) a total news
coverage solution with NNW Prime. As a
multifaceted organization with an extensive team of contributing
journalists and writers, NNW is uniquely positioned to best serve
private and public companies that desire to reach a wide audience
of investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Lexaria Bioscience (CSE:LXX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Lexaria Bioscience (CSE:LXX)
Historical Stock Chart
From Aug 2023 to Aug 2024